Increase of interferon-γ-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy

Clinical Endocrinology

Volumn 64, Issue 2, 2006, Pages 189-195

  Antonelli, Alessandro ^a,d   Rotondi, Mario ^b   Fallahi, Poupak ^a   Romagnani, Paola ^c   Ferrari, Silvia Martina ^a   Barani, Lucio ^a   Ferrannini, Ele ^a   Serio, Mario ^c  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; THIAMAZOLE;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HEALTH STATUS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SERUM; SEX DIFFERENCE; THYROID FUNCTION; TOXIC GOITER;

ADULT; ANTIBODIES; ANTITHYROID AGENTS; CHEMOKINES, CXC; CROSS-SECTIONAL STUDIES; FEMALE; GOITER, NODULAR; GRAVES DISEASE; HUMANS; INTERFERON TYPE II; MALE; METHIMAZOLE; MIDDLE AGED; PHENOTYPE; RECEPTORS, THYROTROPIN; THYROID GLAND; THYROIDITIS, AUTOIMMUNE; THYROTROPIN; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 33645037851     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02447.x     Document Type: Article

References (39)

1. Zlotnik A. Yoshle O. 2000 Chemokines: a new classification system and their role in immunity Immunity 12 121 127
2. Arenberg D.A. Polverini P.J. Kunkel S.L. Shanafelt A. Hesselgesser J. Horuk R. Strieter R.M. 1997 The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer Journal of Leukocyte Biology 62 554 562
3. Muller A. Homey B. Soto H. Ge N. Catron D. Buchanan M.E. McClanahan T. Murphy E. Yuan W. Wagner S.N. Barrera J.L. Mohar A. Verastegui E. Zlotnik A. 2001 Involvement of chemokine receptors in breast cancer metastasis Nature 410 50 56
4. Rotondi M. Lazzeri E. Romagnani P. Serio M. 2003 Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field Journal of Endocrinological Investigation 26 177 180
5. Shimada A. Morimoto J. Kodama K. Suzuki R. Oikawa Y. Funae O. Kasuga A. Saruta T. Narumi S. 2001 Elevated serum IP-10 levels observed in type 1 diabetes Diabetes Care 24 510 515
6. Nicoletti F. Conget I. Di Mauro M. Di Marco R. Mazzarino M.C. Bendtzen K. Messina A. Gomis R. 2002 Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease Diabetologia 45 1107 1110
7. Romagnani P. Rotondi M. Lazzeri E. Lasagni L. Francalanci M. Buonamano A. Milani S. Vitti P. Chiovato L. Tonacchera M. Bellastella A. Serio M. 2002 Expression of IP-10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of subjects with recent onset Graves' disease American Journal of Pathology 161 195 206
8. Antonelli A. Rotondi M. Fallahi P. Romagnani P. Ferrari S.M. Buonamano A. Ferrannini E. Serio M. 2004 High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism Journal of Clinical Endocrinology and Metabolism 89 5496 5499
9. Antonelli A. Rotondi M. Fallahi P. Romagnani P. Ferrari S.M. Paolicchi A. Ferrannini E. Serio M. 2005 Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis European Journal of Endocrinology 152 171 177
10. Garcià-Lòpez M.A. Sancho D. Sànchez-Madrid F. Marazuela M. 2001 Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes Journal of Clinical Endocrinology and Metabolism 86 5008 5016
11. Kemp E.H. Metcalfe R.A. Smith K.A. Woodroofe M.N. Watson P.F. Weetman A.P. 2003 Detection and localization of chemokine gene expression in autoimmune thyroid disease Clinical Endocrinology 59 207 213
12. Romagnani P. Annunziato F. Lasagni L. Lazzeri E. Beltrame C. Francalanci M. Uguccioni M. Galli G. Cosmi L. Maurenzig L. Baggiolini M. Maggi E. Romagnani S. Serio M. 2001 Cell cycle dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity Journal of Clinical Investigation 107 53 63
13. Ashhab Y. Dominguez O. Sospedra M. Roura-Mir C. Lucas-Martin A. Pujol-Borrell R. 1999 A one-tube polymerase chain reaction protocol demonstrates CC chemokine overexpression in Graves' disease glands Journal of Clinical Endocrinology and Metabolism 84 2873 2882
14. Antonelli A. Fallahi P. Nesti C. Pupilli C. Marchetti P. Takasawa S. Okamoto H. Ferrannini E. 2001 Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease Clinical and Experimental Immunology 126 426 431
15. Antonelli A. Ferri C. Fallahi P. 1999 Thyroid cancer in patients with hepatitis C infection Journal of the American Medical Association 281 1588
16. Antonelli A. Miccoli P. Fallahi P. Grosso M. Nesti C. Spinelli C. Ferrannini E. 2003 Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer Thyroid 13 479 484
17. Wesche M.F. Tiel-van Buul M.M. Smits N.J. Wiersinga W.M. 1998 Ultrasonographic versus scintigraphic measurements of thyroid volume in patients referred for 131I therapy Nuclear Medicine Communications 19 341 346
18. Vitti P. 2000 Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease European Journal of Endocrinology 142 22 24
19. Antonelli A. Miccoli P. Fallahi P. Grosso M. Nesti C. Spinelli C. Ferrannini E. 1995 Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer Thyroid 5 25 29
20. Vitti P. Rago T. Mazzeo S. Brogioni S. Lampis M. De Liperi A. Bartolozzi C. Pinchera A. Martino E. 1995 Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis Journal of Endocrinological Investigation 18 857 861
21. Salvi M. Girasole G. Pedrazzoni M. Passeri M. Giuliani N. Minelli R. Braverman L.E. Roti E. 1996 Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease Journal of Clinical Endocrinology and Metabolism 81 2976 2979
22. Salvi M. Pedrazzoni M. Girasole G. Giuliani N. Minelli R. Wall J.R. Roti E. 2000 Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking European Journal of Endocrinology 143 197 202
23. Miyauchi S. Matsuura B. Onji M. 2000 Increased levels of serum interleukin-18 in Graves' disease Thyroid 10 815 859
24. Celik I. Akalin S. Erbas T. 1995 Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment European Journal of Endocrinology 132 668 672
25. Lakatos P. Foldes J. Horvath C. Kiss L. Tatrai A. Takacs I. Tarjan G. Stern P.H. 1997 Serum interleukin-6 and bone metabolism in patients with thyroid function disorders Journal of Clinical Endocrinology and Metabolism 82 78 81
26. Siddiqi A. Monson J.P. Wood D.F. Besser G.M. Burrin J.M. 1999 Serum cytokines in thyrotoxicosis Journal of Clinical Endocrinology and Metabolism 84 435 439
27. Watson P.F. Pickerill A.P. Davies R. Weetman A.P. 1994 Analysis of cytokine gene expression in Graves' disease and multinodular goiter Journal of Clinical Endocrinology and Metabolism 79 355 360
28. Pichler R. Maschek W. Hatzl-Griesenhofer M. Huber H. Crespillo-Gomez C. Berg J. 2003 Soluble tumour necrosis factor-alpha receptor I and interleukin-6 as markers of activity in thyrotoxic Graves' disease Hormone and Metabolic Research 35 427 433
29. Diez J.J. Hernanz A. Medina S. Bayon C. Iglesias P. 2002 Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function Clinical Endocrinology 57 515 521
30. Tsatsoulis A. Vlachoyiannopoulos P.G. Dalekos G.N. Johnson E.O. Moutsopoulos H.M. 1996 Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs European Journal of Clinical Investigation 26 341
31. Cooper D.S. 1984 Antithyroid drugs New England Journal of Medicine 311 1353 1362
32. Weetman A.P. McGregor A.M. Hall R. 1984 Evidence for an effect of antithyroid drugs on the natural history of Graves' disease Clinical Endocrinology 21 163 172
33. Weetman A.P. Tandon N. Morgan B.P. 1992 Anti-thyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells Lancet 340 633 636
34. Senturk T. Kozaci L.D. Kok F. Kadikoylu G. Bolaman Z. 2003 Proinflammatory cytokine levels in hyperthyroidism Clinical and Investigative Medicine 26 58 63
35. Aniszewski J.P. Valyasevi R.W. Bahn R.S. 2000 Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy Journal of Clinical Endocrinology and Metabolism 85 776 780
36. Sorensen T.L. Tani M. Jensen J. Pierce V. Lucchinetti C. Folcik V.A. Qin S. Rottman J. Sellebjerg F. Strieter R.M. Frederiksen J.L. Ransohoff R.M. 1999 Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients Journal of Clinical Investigation 103 807 815
37. Franciotta D. Martino G. Zardini E. Furlan R. Bergamaschi R. Andreoni L. Cosi V. 2001 Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies Journal of Neuroimmunology 115 192 198
38. Gandur V. Simons F.F. Hayglass K.T. 1998 Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL4 response FASEB Journal 12 705 718
39. Mahad D.J. Howell S.J. Woodroofe M.N. 2002 Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis Journal of Neurology Neurosurgery and Psychiatry 72 498 502